EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

"It used to take eight to 10 years to develop a vaccine. But it only took 11 months from the SARS-CoV-2 being gene-sequenced ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new ...

The Vermont pandemic death total stands at 1,289 as of April 19, 2025, with 1 reported death from the previous week (the most ...

RiverStone Health encourages everyone to receive the updated COVID-19 vaccine as recommended by the Centers for Disease ...

All adults 65 years and older are eligible for a second dose of COVID-19 vaccine six months after their previous dose. RiverStone Health is offering a series of walk-in clinics ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

It also found RSV patients had higher ICU admission rates than COVID-19 patients with updated vaccines. RSV, often assumed to be a childhood illness, is a significant threat to seniors and those ...

State public health laboratory also reports an increase in influenza B cases. In December, only 23.4% of the fever cases ...

Vermont has the second lowest state fatality rate in the US (146.9 per 100K; Hawaii 112.8/100K). Mississippi (464.2/100K) and ...